QuickLinks
 -- Click here to rapidly navigate through this document

	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.


 
 

Exhibit 10.29    
    













Veridex,
LLC

1001 US Route 202

Raritan, NJ 08869-0606 


November
10, 2003 














Ed
Erickson,

Chairman and CEO

Immunicon Corporation

3401 Masons Mill Road, Suite 100

Huntingdon Valley, PA 19006-3574 


Subject:
Development, License and Supply Agreement between Immunicon Corporation and Ortho-Clinical Diagnostics, Inc. dated August 17, 2000. 


Dear
Ed: 


        As
you know, all of the business of Advanced Diagnostic Systems is now conducted by Veridex, LLC, and Veridex, LLC assumes all the rights, interests, and obligations under the subject
Agreement. Veridex LLC represents that it is an "Affiliate" of Ortho-Clinical Diagnostics, Inc., and not a "Third Party" as those terms are defined in the subject Agreement, and that Veridex,
LLC has the full right and power to assume all the rights, interests and obligations of Ortho-Clinical Diagnostics, Inc. under the subject Agreement without the prior written consent of
Immunicon Corporation, pursuant to section 16.3.1(a)(i) of the subject Agreement. 


        We
propose modifying the subject Agreement by nullifying all milestones described in section 5 that have not yet been fully performed (except for the milestone enumerated in
section 5.2.6, as clarified in the attached table (new Exhibit X), which milestone shall remain executory). However, the parties have jointly reviewed the project and have determined
that the CellTracks technology will not be available at a time sufficient to meet the portion of the milestone described in section 5.2.6 that refers to such technology. Accordingly, the last
sentence of such milestone shall be stricken from the Agreement and the adjustment described beneath the attached table shall be made. The following milestone provisions shall also be added in place
of those which have been nullified. Where the same event appears in more than one milestone, it establishes the order or timing in which events are to occur and does not require repetition of that
event. Additionally, a new section 3.5.1 is provided to completely replace that section as currently drafted in the Agreement and a new Exhibit Y is provided. All other terms and
conditions of the Agreement shall remain the same. Please indicate your acceptance by signing in the appropriate space below. 



        3.5.1    Immunicon
shall allocate a budget covering all Clinical Trial Expenses for Cellular Analysis Products for all monitoring, adjuvant, recurrence, companion biopsy, and
all other non-screening indications described or referred to in this Agreement, and shall bear up to Five Million dollars (US$5,000,000) for Clinical Trial Expenses for the first Cellular
Analysis Product for screening the general population for a major cancer as may be agreed to by the Steering Committee and provided, upon review of the data produced in such Clinical Trial, the
Steering Committee continues to approve such Clinical Trial. If such screening Clinical Trial Expenses exceed Five Million dollars (US$5,000,000) then Immunicon shall not be obligated to pay any such
excess amount and OCD shall pay up to Five Million dollars (US$5,000,000) of such additional screening Clinical Trial Expenses. If such additional screening Clinical Trial Expenses exceed Five Million
Dollars ($5,000,000), then the parties shall negotiate in good faith the future terms and conditions under which Clinical Trial for Cellular Analysis Products for such screening will be funded. OCD
shall also pay the reasonable incremental Clinical Trial Expenses attributable to indications in support of OCD products or methods for diagnostic testing 








or
testing for determinations regarding therapy based on [**]. Immunicon shall keep accurate records of the incremental Clinical Trial Expenses to be borne by OCD under this
Section 3.5.1 and shall provide OCD with an itemized list and description of such expenses in sufficient detail for OCD to assess their validity. Immunicon shall provide OCD with such a list
within 90 days of the accrual of such expenses. OCD shall pay to Immunicon such reasonable incremental Clinical Trial Expenses within 60 days of receipt of such list. The list provided
by Immunicon under this Section 3.5.1 shall be subject to the Audit Rights set forth in Section 3.6.3. 


        5.2.10    Metastatic
Colorectal or Prostate Cancer Therapy Monitoring. 



        5.2.10.1    [**]
upon initiation of a Clinical Trial for a Cellular Analysis Product in support of metastatic colorectal or prostate Cancer therapy
monitoring, and prediction/prognostic claims. This milestone shall be complete when all of the following activities have been completed: (a) the Steering Committee selects the Cancer to which
this milestone shall be directed
(i.e., either colorectal or prostate) (b) approval by the Steering Committee of a Clinical Trial protocol, (c) delivery of the protocol to the FDA for comment, (d) Principal
Investigator and Institutional Review Board approval has been obtained in three (3) clinical sites for conducting the Clinical Trial, (e) clinical sites have been trained, are under
contract, and materials have been delivered, and (f) the first patient has been enrolled in such a Clinical Trial. The completion date for this milestone is [**]. 



        5.2.10.2    [**]
upon the transfer to OCD of a draft appropriate regulatory submission for the FDA of a Cellular Analysis Product that includes a
therapy monitoring claim for metastatic colorectal or prostate Cancer. This milestone shall be complete when all of the following activities have been completed: (a) OCD is in receipt of such a
draft submission incorporating data and information that is pertinent to Immunicon's responsibilities under this Agreement, and (b) the Steering Committee has approved such submission as
properly prepared for transfer to the FDA. The completion date for this milestone is [**]. 




        5.2.11    Prostate
Cancer: [**] 



        5.2.11.1    [**]
upon the successful demonstration by Immunicon that a Cellular Analysis Product is suitable, in combination with either a method or
assay [**]. This milestone shall be complete when all of the following activities have been completed: (a) provide OCD with a complete report of research results
relating to the use of Cellular Analysis Products on [**], (b) obtain the acceptance of the Steering Committee for a proposed method for Large Volume sample processing
to enable [**] of whole blood to be used on the automated sample preparation system (the current version of which is referred to as the AutoPrep device) with a single tube for
clinical investigations, (c) demonstrate a method to be used on such automated sample preparation system capable of preparing a clinical sample for use in this application from
[**] of whole blood [**], (d) [**], (e) [**], (f) propose
[**] compatible with the automated sample preparation system sample tube that can be processed on such system and analyzed on the Automated Cell Analysis System (the current
version of which is referred to as the CellTracks instrument), and (g) summarize results from these experiments to the Steering Committee and determine (along with the involvement of OCD) the
best approach for developing a process likely to obtain Regulatory Approval for [**]; wherein, in each of the foregoing requirements, data shall have been obtained according to
protocols set form in Exhibit Y as such exhibit shall be modified from time to time by the parties. The completion date for this milestone is [**]. 



	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.






        5.2.11.2.    [**]
upon the initiation of a Clinical Trial for evaluating the use of a Cellular Analysis Product produced by Immunicon in combination
with a method or assay [**]. This milestone shall be complete when all of the following activities have been completed: (a) conduct a Clinical Trial readiness review and
obtain Steering Committee approval of a Clinical Trial protocol for this application that includes cell capture with the use of Immunicon Cellular Analysis Products [**],
(b) delivery of the protocol to the FDA for comments, (c) Principal Investigator and Institutional Review Board approval has been obtained in [**] clinical sites
for conducting the Clinical Trial, (d) clinical sites have been trained, are under contract, and materials have been delivered, and (e) the first patient has been enrolled in such a
Clinical Trial. The completion date for this milestone is [**]. 


        5.2.11.3    [**]
upon transfer to OCD of a properly prepared appropriate regulatory submission for FDA approval for a Cellular Analysis Product that
includes a claim for the use of a Cellular Analysis Product produced by Immunicon by itself or in combination with a method or assay [**]. This milestone shall be complete when
all of the following activities have been completed: (a) OCD is in receipt of such a submission incorporating data and information that is pertinent to Immunicon's responsibilities under this
Agreement, and (b) the Steering Committee has approved such submission as properly prepared for transfer to the FDA. The completion date for this milestone is [**]. 




        5.2.12    Lung
Cancer Adjuvant Prognosis and Recurrence Monitoring. 



        5.2.12.1    [**]
upon initiation of a Clinical Trial for a Cellular Analysis Product in support a non-small cell lung Cancer prognostic
claim in the adjuvant setting and a non-small cell lung Cancer recurrence monitoring claim. This milestone shall be complete when all of the following activities have been completed:
(a) approval by the Steering Committee of a Clinical Trial protocol which includes cell enumeration and cell capture with the use of Immunicon Cellular Analysis Products and
[**] (b) delivery of the protocol to the FDA for comments, (c) Principal Investigator and Institutional Review Board approval has been obtained in
[**] clinical sites for conducting the Clinical Trial, (d) clinical sites have been trained, are under contract, and the materials have been delivered to them, and
(e) the first patient had been enrolled in such a Clinical Trial that uses the Automated Cell Analysis System and associated sample preparation instrumentation (the current versions of which
are referred to as CellTracks and AutoPrep instruments, respectively). The completion date for this milestone is [**]. 



        5.2.12.2    [**]
upon the completion of an interim patient accrual review for a fully accrued Clinical Trial for a Cellular Analysis Product in support
of a non-small cell lung Cancer prognostic claim in the adjuvant setting and a non-small cell lung Cancer recurrence monitoring claim. This milestone shall be complete when all
of the following activities have been completed: (a) at least [**] of the target number of subjects (as determined by the Steering Committee) have been enrolled in the
Clinical Trial according to the protocol referred to above and meet inclusion/exclusion criteria, and upon the completion of this activity, (b) a progress review with all relevant reportable
results, including demographics, and updated timeline has been presented to the Steering Committee and approval has been obtained, (c) all relevant background data necessary to support the
Clinical Trial concerning the subjects has been obtained, summarized, presented to, and accepted by the Steering Committee. The completion date for this milestone is [**]. 



	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.






        5.2.12.3    [**]
upon the transfer to OCD of a properly prepared appropriate regulatory submission for a Cellular Analysis Product in support of a
non-small cell lung Cancer prognostic claim in the adjuvant setting. This milestone shall be complete when all of the following activities have been completed: (a) OCD is in receipt
of such a submission for each of the claims incorporating data and information that is pertinent to Immunicon's responsibilities under this Agreement and (b) the Steering Committee has approved
such submission as properly prepared for transfer to the FDA. The completion date for this milestone is [**]. 




        5.2.13    Colorectal
or Breast Cancer Adjuvant Prognosis and Recurrence Monitoring. 



        5.2.13.1    [**]
upon initiation of a Clinical Trial for a Cellular Analysis Product with a colorectal or breast Cancer prognostic claim in the adjuvant
setting and a colorectal or breast Cancer recurrence monitoring claim. This milestone shall be complete when all of the following activities have been completed: (a) the Steering Committee
selects the Cancer to which this milestone shall be directed (i.e., either colorectal or breast) (b) approval by the Steering Committee of a Clinical Trial protocol which includes cell
enumeration and cell capture with the use of Immunicon Cellular Analysis Products and [**] (c) delivery of the protocol to the FDA for comments, (d) Principal
Investigator and Institutional Review Board approval has been obtained in [**] clinical sites for conducting the Clinical Trial, (e) clinical sites have
been trained, are under contract, and, the materials have been delivered to them, and (f) the first patient has been enrolled in a Clinical Trial that uses the Automated Cell Analysis System
and associated sample preparation instrumentation (the current versions of which are referred to as CellTracks and AutoPrep instruments, respectively). The completion date for this milestone is
[**]. 


        5.2.13.2    [**]
upon the completion of an interim patient accrual review of a fully accrued Clinical Trial for a Cellular Analysis Product with a
colorectal or breast Cancer prognostic claim in the adjuvant setting and a colorectal or breast Cancer recurrence monitoring claim. This milestone shall be complete when all of the following
activities have been completed: (a) at least [**] of the target number of subjects (as determined by the Steering Committee) have been enrolled in the Clinical Trial and
meet the inclusion/exclusion criteria as set forth in the protocol referred to above, and upon completion of this activity, (b) a progress review with all relevant reportable results, including
demographics, and updated timeline has been presented to the Steering Committee and approval has been obtained and (c) all relevant background data necessary to support the Clinical Trial
concerning the subjects has been obtained, summarized, presented to, and accepted by the Steering Committee. The completion date for this milestone is [**]. 


        5.2.13.3    [**]
upon the transfer of OCD of a properly prepared appropriate regulatory submission for a Cellular Analysis Product in support of a
colorectal or breast Cancer prognostic claim in the adjuvant setting. This milestone shall be complete when all of the following activities have been completed: (a) OCD is in receipt of such a
submission for each of the claims incorporating data and information that is pertinent to Immunicon's responsibilities under this Agreement and (b) the Steering Committee has approved such
submission as properly prepared for transfer to the FDA. The completion date for this milestone is [**]. 




        5.2.14    Tumor
Cell Profiling with Analyte Specific Reagents. [**] upon the development of assay components comprising antibodies, and similar
substances formulated as reagents which, through the use of Immunicon Technology, can be used in a diagnostic application for identification and characterization of Cancer cells (tumor cell profiling
reagents). This milestone shall be complete when all of the following activities have been completed: (a) the Steering Committee has approved a formal Product Development Process by which such
reagents will be developed, (b) such reagents for the detection of [**] have been fully developed and 


	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.






the
first commercially saleable lot of such reagent has been produced by [**], or [**] months after Immunicon receives a forecast from OCD,
whichever occurs later (c) such reagents for the detection of the [**] have been initially developed and have successfully completed a Production Readiness Review by
[**], according to the process set forth in 5.2.14(a) above, and (c) commercial rights for suitable antibodies to be used commercially for detecting
[**] have been obtained and the commercial suitability of their use has been demonstrated and approved by the Steering Committee. The completion date for this milestone is
[**]. 


        5.2.15.    Large
Volume Sample Processing. [**] upon the complete development and Regulatory Approval by FDA of a commercially viable method for
processing large volume samples of whole blood in Immunicon Automated Cell Analysis Systems. This milestone shall be complete when all of the following activities have been completed: (a) the
Steering Committee has approved a regulatory and clinical strategy regarding such method (b) such a device and method for processing at least [**] of whole blood has
been developed and the clinical and regulatory strategy has been implemented, (c) appropriate Regulatory Approval of the process is obtained, and (d) Immunicon Automated Cell Analysis
Systems are available for commercial use and are capable of performing such method without a need for further modification. The completion date for this milestone is [**]. 


	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.





 
 

Exhibit X: Revised Milestone Table(6)    
    



	MS

#
	 	Agmt

Section
	 	Title
	 	SubTitle
	 	Target

Date
	 	Adjustment
	 	Successful Completion

Criteria
	 	Sample

Process
	 	Detection
	 	Note
	 	Amount

($US)

	6	 	5.2.6	 	Commercial Readiness for Breast Cancer Therapy Monitoring	 	 	 	[**]	 	See Note 2a	 	Steering Committee approves product release for sale of a FDA-approved breast cancer therapy monitoring system and completion of other criteria set forth in 5.2.6	 	AutoPrep	 	CellTracks	 	1	 	[**] See Note 2
	

7a	
 	

5.2.10.1	
 	

Metastatic Colorectal or Prostate Cancer Monitoring: (with prognostic and prediction claims)	
 	

Initiate Clinical Study	
 	

[**]	
 	

[**]	
 	

Protocol approved by OCD and IC and sent to FDA, clinical sites ready, and first patient enrolled	
 	

AutoPrep	
 	

CellTracks	
 	

3	
 	

[**]
	

7b	
 	

5.2.10.2	
 	

"	
 	

Deliver Draft Regulatory Submission to OCD	
 	

[**]	
 	

[**]	
 	

Steering Committee approves regulatory submission	
 	

AutoPrep	
 	

CellTracks	
 	

 	
 	

[**]
	

8a	
 	

5.2.11.1	
 	

Prostate Cancer: [**]	
 	

Feasibility Complete	
 	

[**]	
 	

[**]	
 	

Demonstrate feasibility of Large Blood Volume Method [**], and propose product concept	
 	

AutoPrep	
 	

CellTracks	
 	

4: Exhibit Y	
 	

[**]
	

8b	
 	

5.2.11.2	
 	

"	
 	

Initiate Clinical Study	
 	

[**]	
 	

[**]	
 	

Steering Committee approves Trial readiness, protocol sent to FDA, sites ready, and first patient enrolled	
 	

AutoPrep	
 	

CellTracks	
 	

3

5	
 	

[**]
	

8c	
 	

5.2.11.3	
 	

"	
 	

Deliver Regulatory Submission to OCD	
 	

[**]	
 	

[**]	
 	

Steering Committee approves regulatory submission for adjuvant prognosis	
 	

AutoPrep	
 	

CellTracks	
 	

 	
 	

[**]
	

9a	
 	

5.2.12.1	
 	

Lung Cancer: Adjuvant Prognosis and Recurrence Monitoring	
 	

Initiate Clinical Study	
 	

[**]	
 	

[**]	
 	

Steering Committee approves readiness, protocol sent to FDA, sites ready, and first patient enrolled	
 	

AutoPrep	
 	

CellTracks	
 	

3

5	
 	

[**]
	

9b	
 	

5.2.12.2	
 	

"	
 	

Interim Patient Accrual Review	
 	

[**]	
 	

[**]	
 	

[**] of patients properly accrued and progress review/timeline approved by Steering Committee	
 	

AutoPrep	
 	

CellTracks	
 	

 	
 	

[**]
	

9c	
 	

5.2.12.3	
 	

"	
 	

Deliver Regulatory Submission to OCD	
 	

[**]	
 	

[**]	
 	

Steering Committee approves regulatory submission	
 	

AutoPrep	
 	

CellTracks	
 	

 	
 	

[**]
	

10a	
 	

5.2.13.1	
 	

Colorectal or Breast Cancer: Adjuvant Prognosis and Recurrence Monitoring	
 	

Initiate Clinical Study	
 	

[**]	
 	

[**]	
 	

Steering Committee approves readiness, protocol sent to FDA, sites ready, and first patient enrolled	
 	

AutoPrep	
 	

CellTracks	
 	

3

5	
 	

[**]
	

10b	
 	

5.2.13.2	
 	

"	
 	

Interim Patient Accrual Review	
 	

[**]	
 	

[**]	
 	

[**] of patients properly accrued and progress review/timeline approved by Steering Committee	
 	

AutoPrep	
 	

CellTracks	
 	

 	
 	

[**]




	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.







	10c	 	5.2.13.3	 	"	 	Deliver Regulatory Submission to OCD	 	[**]	 	[**]	 	Steering Committee approves regulatory submission for adjuvant prognosis	 	AutoPrep	 	CellTracks	 	 	 	[**]
	11	 	5.2.14	 	Tumor Cell Profiling	 	[**]	 	[**]	 	[**]	 	Steering Committee approves Prod Dev Process, [**] commercially available, [**] completes Production Readiness Review, and [**] has demonstrated proof of principle and acquired antibody	 	AutoPrep	 	CellTracks	 	 	 	[**]
	12	 	5.2.15	 	Large Volume Sample Processing	 	 	 	[**]	 	[**]	 	Development and Steering Committee approved clinical/regulatory strategy completed; commercial readiness with regulatory approval	 	AutoPrep	 	CellTracks	 	 	 	[**]







Notes related to Milestones in table: 


	1.
	The
following minimum requirements must be met:



	•
	FDA
regulatory approval received



	•
	Minimum
3 lots of materials manufactured under GMP compliance (or current FDA standard for lots and quality compliance)



	•
	Demonstrated
ability to produce the forecasted quantities of materials



	•
	Inventory
in place for Commercial Launch






	2.
	[**]
will be paid upon receipt of FDA approval for the Breast Cancer Therapy Monitoring submission based on the IMMC01 trial using semi-automated
sample processing (CellPrep) and CellSpotter. The remaining [**] will be paid upon completion of the milestone as defined in the table. 



2a.
The parties agree that there shall be no completion date subject to adjustment under Section 5.4 for this milestone 5.2.6, and that in lieu thereof Immunicon's share of Net Sales of the
Cellular Analysis Product to which this milestone relates, under Section 6.2, shall be set at [**]. 



	3.
	A
minimum of [**] clinical sites will have achieved approval and sign-off from Principal Investigator and from IRB. Clinical sites will have been
trained, under contract, and materials will have been delivered.



	4.
	Exhibit Y
identifies the experiments planned to address the identified criteria. These experiments may be modified with agreement between OCD and Immunicon.



	5.
	In
addition to cell enumeration, blood will also be processed with [**] and [**] will be processed and stored for testing.



	6.
	This
table is a summary of milestone information from the Agreement. Any interpretation of the milestone provisions shall be governed by the terms set forth in the text of the
Agreement.



	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.





 
 

Exhibit Y: Requirements for the Large Volume Sample Processor to be used for the Prostate Cancer [**] Milestone(a)(b)    
    


	1.
	The
Large Volume Sample Processor (LVSP) must meet its functional requirements using whole blood collected in CellSave tubes.



	2.
	The
LVSP will process a large (up to [**] mLs) volume of whole blood and deliver a tumor cell enriched fraction into a standard AutoPrep sample tube, such that
the sample may then be placed on AutoPrep without further pre-processing.



	3.
	The
LVSP must demonstrate the number of recovered cells using the [**] mL blood volume reduction protocol is at least [**] the number
recovered when using [**] mL samples. This will be measured after LVSP processing, but before AutoPrep cell enrichment sample processing (AutoPrep input):



	•
	The
total number of leukocytes recovered from a [**] mL whole blood sample processed using the LVSP is at least [**] the
number of leukocytes recovered from [**] mLs of whole blood.






	4.
	Processing
of Tumor cell lines on the LVSP should not affect negatively their ability to be recovered by AutoPrep, or the accuracy of their reading on CellSpotter and/or CellTracks.
This will be measured after LVSP and AutoPrep / Cell enrichment sample processing (AutoPrep Output):



	•
	The
leukocyte carryover into a CellTracks chamber from LVSP processed samples should not exceed, on average, the leukocyte carryover of the sum of
[**] whole blood samples when processed on AutoPrep.



	•
	The
total number of spiked tumor cells recovered from a [**] mL whole blood sample processed using the LVSP is at least [**]
the number of tumor cells recovered from [**] of whole blood. Testing should be conducted at a tumor cell spike level of [**] mLs.






	5.
	The
Normal Reference Range should be less than or equal to [**] that of a single [**] mL tube. The functional sensitivity for tumor cell
detection per mL of sample (as determined by titrating spiked cells) must be [**] lower than that of a single [**] mL tube. For example, if the
functional sensitivity determined in a [**] mL sample is [**], then the functional sensitivity determined in a [**] mL sample
must be less than or equal to [**]. Working with the LVSPs New Product Proposal, or equivalent design control document, which incorporates the MECs, the Normal Reference Range
and the functional sensitivity shall be judged by the Steering Committee as to the LVSP's acceptability for its intended use.



	6.
	Demonstrate
that the LVSP processing, followed by AutoPrep sample enrichment is compatible with [**] analysis of the enriched cell population. The quality of
the [**] must be similar to that obtained from [**] mL samples. 




	(a)
	The
experiments used to demonstrate performance will be designed by Immunicon personnel, and performed according to written protocols. In advance of their execution, the Steering
Committee must agree that the design will yield results that adequately, and properly address the performance being tested.



	**
	Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential
treatment request under 17 C.F.R. Sections 200.80(b)(4), 200.83 and 230.406.





	(b)
	The
analysis platform for feasibility experiments will be either CellSpotter or CellTracks. If Cell Spotter is used for feasibility demonstration, then equivalence must be
demonstrated on CellTracks 






	 	 	Veridex, LLC
	

 	
 	

By:	
 	

/s/ ROY N. DAVIS
 Roy N. Davis

President





	ACCEPTED AND AGREED	 	 
	

IMMUNICON CORPORATION	
 	

 
	

By:	
 	

/s/ EDWARD L. ERICKSON
	
 	

 
	Name:	 	Edward L. Erickson
	 	 
	Title:	 	Chairman, President & CEO
	 	 
	Date:	 	11/13/03
	 	 











QuickLinks



Exhibit 10.29


Exhibit X: Revised Milestone Table(6)

Exhibit Y: Requirements for the Large Volume Sample Processor to be used for the Prostate Cancer [**] Milestone(a)(b)